EBSWORTH DAVID R 4

4 · Verona Pharma plc · Filed Feb 28, 2025

Form 4

Period: 2025-02-26

Director

Transactions

Gift
Ordinary Shares
2025-02-26−64,000→ 1,336,003 total
Exercise/Conversion
Ordinary Shares
2025-02-26$0.78/sh+64,000$49,600→ 1,004,003 total
Exercise/Conversion
Ordinary Shares
2025-02-26$0.50/sh+200,000$100,760→ 1,204,003 total
Exercise/Conversion
Ordinary Shares
2025-02-26$1.93/sh+100,000$193,380→ 1,400,003 total
Exercise/Conversion
Share Option (Right to Exercise)
2025-02-26−200,000→ 0 total
Exercise: $0.50Exp: 2032-04-27→ Ordinary Shares (200,000 underlying)
Exercise/Conversion
Share Option (Right to Exercise)
2025-02-26−96,000→ 0 total
Exercise: $2.67Exp: 2033-04-27→ Ordinary Shares (96,000 underlying)
Exercise/Conversion
Ordinary Shares
2025-02-26$2.67/sh+96,000$256,320→ 1,300,003 total
Exercise/Conversion
Share Option (Right to Exercise)
2025-02-26−64,000→ 0 total
Exercise: $0.78Exp: 2031-08-08→ Ordinary Shares (64,000 underlying)
Exercise/Conversion
Share Option (Right to Exercise)
2025-02-26−100,000→ 140,000 total
Exercise: $1.93Exp: 2034-04-28→ Ordinary Shares (100,000 underlying)

Footnotes (5)

[F1]Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.
[F2]Consists of (i) 1,336,000 Ordinary Shares represented by 167,000 ADSs and (ii) 3 Ordinary Shares.
[F3]The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.
[F4]The option is fully vested.
[F5]The option vests and becomes exercisable as to 25% on each of July 29, 2024, October 29, 2024, January 29, 2025 and April 29, 2025.

Documents

1 file